Immunotherapy plus chemoradiation for stomach cancer before surgery
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving immunotherapy (a treatment that helps your immune system fight cancer) along with chemotherapy and radiation before surgery can help shrink tumors in people with stomach cancer at the esophagus-stomach junction. The goal is to see if this approach is safe and effective before the main surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of stomach cancer (adenocarcinoma) at the junction of the esophagus and stomach that has not spread far.
- You have not had any previous cancer treatment, such as surgery, chemotherapy, or radiation.
- You are generally able to take care of yourself (performance status 0 or 1).
- Your blood counts and organ functions (kidney, liver, blood clotting) are within acceptable ranges.
- You do not have other active cancers, autoimmune diseases, or serious heart/lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a short course of radiation to a combination of chemotherapy and an immunotherapy drug (called a PD-1 inhibitor) before surgery helps shrink tumors and improve outcomes for people with upper stomach or gastroesophageal junction cancer.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
This study tests a combination of an immunotherapy drug (tislelizumab) with two chemotherapy drugs (called the SOX regimen) given before surgery for locally advanced stomach cancer. The goal is to see if this treatment can shrink the tumor and make it easier to remove completely during surgery.
This trial tests giving an immunotherapy drug (adebrelimab) along with two chemotherapy drugs (capecitabine and oxaliplatin) before and after surgery for a specific type of stomach-cancer junction tumor. It aims to see if this combination is safe and effective in shrinking the tumor and improving outcomes.
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
Hear when a new Adenocarcinoma of Esophagogastric Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.